Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients

被引：16

作者：

Amaral, N. B. ^{[1
]}

Rodrigues, T. S. ^{[2
]}

Giannini, M. C. ^{[1
]}

Lopes, M. I. ^{[1
]}

Bonjorno, L. P. ^{[1
]}

Menezes, P. I. S. O. ^{[1
]}

Dib, S. M. ^{[1
]}

Gigante, S. L. G. ^{[1
]}

Benatti, M. N. ^{[1
]}

Rezek, U. C. ^{[1
]}

Emrich-Filho, L. L. ^{[1
]}

Sousa, B. A. ^{[1
]}

Almeida, S. C. L. ^{[1
]}

Luppino-Assad, R. ^{[1
]}

Veras, F. P. ^{[3
]}

Schneider, A. H. ^{[3
]}

Leiria, L. O. S. ^{[3
]}

Cunha, L. D. ^{[2
]}

Alves-Filho, J. C. ^{[3
]}

Cunha, T. M. ^{[3
]}

Arruda, E. ^{[2
]}

Miranda, C. H. ^{[4
]}

Pazin-Filho, A. ^{[4
]}

Auxiliadora-Martins, M. ^{[5
]}

Borges, M. C. ^{[4
]}

Fonseca, B. A. L. ^{[1
]}

Bollela, V. R. ^{[1
]}

Del-Ben, C. M. ^{[6
]}

Cunha, F. Q. ^{[3
]}

Santana, R. C. ^{[1
]}

Vilar, F. C. ^{[1
]}

Zamboni, D. S. ^{[2
]}

Louzada-Junior, P. ^{[1
]}

Oliveira, R. D. R. ^{[1
]}

机构：

[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, 14-048-900, Ribeirao Preto, SP, Brazil

[2] Univ Sao Paulo, Dept Cell Biol, Ribeirao Preto, SP, Brazil

[3] Univ Sao Paulo, Dept Pharmacol, Ribeirao Preto, SP, Brazil

[4] Univ Sao Paulo, Dept Emergency Med, Ribeirao Preto, SP, Brazil

[5] Univ Sao Paulo, Dept Surg & Anat, Ribeirao Preto, SP, Brazil

[6] Univ Sao Paulo, Behav Ribeirao Preto Med Sch, Dept Neurosci, Ribeirao Preto, SP, Brazil

来源：

INFLAMMATION RESEARCH | 2023年 / 72卷 / 05期

基金：

巴西圣保罗研究基金会;

关键词：

Colchicine; COVID-19; Inflammasome; Cytokines; CORONAVIRUS DISEASE;

D O I：

10.1007/s00011-023-01718-y

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

ObjectiveTo evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.MethodsWe present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1 beta, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.ResultsThirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1 beta.ConclusionTreatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19.

引用

页码：895 / 899

页数：5

共 29 条

[21] Anti-inflammatory therapy for COVID-19 infection: the case for colchicine [J].

Reyes, Aaron Z. ;

Hu, Kelly A. ;

Teperman, Jacob ;

Wampler Muskardin, Theresa L. ;

Tardif, Jean-Claude ;

Shah, Binita ;

Pillinger, Michael H. .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) :550-557

[22] Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation [J].

Robertson, Stacy ;

Martinez, Gonzalo J. ;

Payet, Cloe A. ;

Barraclough, Jennifer Y. ;

Celermajer, David S. ;

Bursill, Christina ;

Patel, Sanjay .

CLINICAL SCIENCE, 2016, 130 (14) :1237-1246

[23] Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients [J].

Rodrigues, Tamara S. ;

de Sa, Keyla S. G. ;

Ishimoto, Adriene Y. ;

Becerra, Amanda ;

Oliveira, Samuel ;

Almeida, Leticia ;

Goncalves, Augusto, V ;

Perucello, Debora B. ;

Andrade, Warrison A. ;

Castro, Ricardo ;

Veras, Flavio P. ;

Toller-Kawahisa, Juliana E. ;

Nascimento, Daniele C. ;

de Lima, Mikhael H. F. ;

Silva, Camila M. S. ;

Caetite, Diego B. ;

Martins, Ronaldo B. ;

Castro, Italo A. ;

Pontelli, Marjorie C. ;

de Barros, Fabio C. ;

do Amaral, Natalia B. ;

Giannini, Marcela C. ;

Bonjorno, Leticia P. ;

Lopes, Maria Isabel F. ;

Santana, Rodrigo C. ;

Vilar, Fernando C. ;

Auxiliadora-Martins, Maria ;

Luppino-Assad, Rodrigo ;

de Almeida, Sergio C. L. ;

de Oliveira, Fabiola R. ;

Batah, Sabrina S. ;

Li Siyuan ;

Benatti, Maira N. ;

Cunha, Thiago M. ;

Alves-Filho, Jose C. ;

Cunha, Fernando Q. ;

Cunha, Larissa D. ;

Frantz, Fabiani G. ;

Kohlsdorf, Tiana ;

Fabro, Alexandre T. ;

Arruda, Eurico ;

de Oliveira, Rene D. R. ;

Louzada-Junior, Paulo ;

Zamboni, Dario S. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (03)

[24] Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy [J].

Silvis, Max J. M. ;

Fiolet, Aernoud T. L. ;

Opstal, Tjerk S. J. ;

Dekker, Mirthe ;

Suquilanda, Daniel ;

Zivkovic, Minka ;

Duyvendak, Michiel ;

The, Salem H. K. ;

Timmers, Leo ;

Bax, Willem A. ;

Mosterd, Arend ;

Cornel, Jan H. ;

de Kleijn, Dominique P., V .

ATHEROSCLEROSIS, 2021, 334 :93-100

[25] Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [J].

Tardif, Jean-Claude ;

Bouabdallaoui, Nadia ;

L'Allier, Philippe L. ;

Gaudet, Daniel ;

Shah, Binita ;

Pillinger, Michael H. ;

Lopez-Sendon, Jose ;

da Luz, Protasio ;

Verret, Lucie ;

Audet, Sylvia ;

Dupuis, Jocelyn ;

Denault, Andre ;

Pelletier, Martin ;

Tessier, Philippe A. ;

Samson, Sarah ;

Fortin, Denis ;

Tardif, Jean-Daniel ;

Busseuil, David ;

Goulet, Elisabeth ;

Lacoste, Chantal ;

Dubois, Anick ;

Joshi, Avni Y. ;

Waters, David D. ;

Hsue, Priscilla ;

Lepor, Norman E. ;

Lesage, Frederic ;

Sainturet, Nicolas ;

Roy-Clavel, Eve ;

Bassevitch, Zohar ;

Orfanos, Andreas ;

Stamatescu, Gabriela ;

Gregoire, Jean C. ;

Busque, Lambert ;

Lavallee, Christian ;

Hetu, Pierre-Olivier ;

Paquette, Jean-Sebastien ;

Deftereos, Spyridon G. ;

Levesque, Sylvie ;

Cossette, Marieve ;

Nozza, Anna ;

Chabot-Blanchet, Malorie ;

Dube, Marie-Pierre ;

Guertin, Marie-Claude ;

Boivin, Guy .

LANCET RESPIRATORY MEDICINE, 2021, 9 (08) :924-932

[26] Inflammasome formation in the lungs of patients with fatal COVID-19 [J].

Toldo, Stefano ;

Bussani, Rossana ;

Nuzzi, Vincenzo ;

Bonaventura, Aldo ;

Mauro, Adolfo G. ;

Cannata, Antonio ;

Pillappa, Raghavendra ;

Sinagra, Gianfranco ;

Nana-Sinkam, Patrick ;

Sime, Patricia ;

Abbate, Antonio .

INFLAMMATION RESEARCH, 2021, 70 (01) :7-10

[27] Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis [J].

Toro-Huamanchumo, Carlos J. ;

Benites-Meza, Jerry K. ;

Mamani-Garcia, Carlos S. ;

Bustamante-Paytan, Diego ;

Gracia-Ramos, Abraham Edgar ;

Diaz-Velez, Cristian ;

Barboza, Joshuan J. .

JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)

[28] Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease [J].

Vecchie, Alessandra ;

Del Buono, Marco Giuseppe ;

Chiabrando, Guido Juan ;

Dentali, Francesco ;

Abbate, Antonio ;

Bonaventura, Aldo .

CURRENT CARDIOLOGY REPORTS, 2021, 23 (11)

[29] Effect of colchicine on mortality in patients with COVID-19 - A systematic review and meta-analysis [J].

Zein, Ahmad Fariz Malvi Zamzam ;

Raffaello, Wilson Matthew .

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (02)

← 1 2 3 →